Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON23516
NL-OMON23516
Not yet recruiting
Not Applicable

BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolation

Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands0 sites30 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsParoxysmal and persistent atrial fibrillation

Overview

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Enrollment
30
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational non invasive

Eligibility Criteria

Inclusion Criteria

  • •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • •1\.Diagnosis of paroxysmal or persistent AF
  • •2\.Subject scheduled to undergo PVI within 6 months
  • •3\.Subject willing and able to comply with the follow\-up requirements of the study
  • •4\.Written informed consent obtained from subject aged 18 years or older

Exclusion Criteria

  • •A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • •1\.Diagnosis of long\-standing persistent AF
  • •2\.Subjects implanted with a previous ICM, pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy device
  • •3\.Subjects with an active infection
  • •4\.Subjects enrolled in another clinical study which may confound the results of this study
  • •5\.Subjects with a life expectancy of \<1 year due to any condition

Investigators

Sponsor
Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Similar Trials

Completed
Not Applicable
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolatioAtrial fibrillationirregular heart rhythm10007521
NL-OMON48234Erasmus MC, Universitair Medisch Centrum Rotterdam30
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-005086-12-HUOctapharma AG216
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globuli
EUCTR2012-005086-12-ATOctapharma AG216
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-005086-12-BGOctapharma AG234
Active, not recruiting
Not Applicable
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-005086-12-DEOctapharma AG216